U.S. & International Scientists to focus on drug therapies, radiopharmaceuticals, and progression of NETs [BOSTON, MA, January 17, 2024–] The Neuroendocrine Tumor Research Foundation (NETRF)

Lung neuroendocrine tumors (NETs) are graded as typical or atypical carcinoids based on how quickly the tumor cells divide. They exhibit diverse clinical behaviors and

Midgut neuroendocrine tumors (NETs), such as small intestinal NETs, originate in the neuroendocrine cells of the midgut, a part of the digestive system, and have

As we reflect on the past year, the Neuroendocrine Tumor Research Foundation (NETRF) takes immense pride in the strides we have made towards understanding and

NETRF’s 2023 Margie and Robert E Petersen Neuroendocrine Tumor Research Symposium brought together a hundred of the world’s foremost neuroendocrine cancer scientists in Boston. The

Almost half of patients diagnosed with pancreatic neuroendocrine tumors (PanNETs) have tumors that have spread to their liver, which correlates with poorer outcomes. Given this,

The Neuroendocrine Tumor Research Foundation celebrates a significant milestone in cancer therapy: a first-in-human CAR T cell therapy clinical trial for neuroendocrine tumors (NETs) will

Through her 2021 NETRF Investigator Award, Lisa Bodei, MD, PhD, professor of radiology at Weill Cornell Medical College, attending physician and director of targeted radionuclide

NETRF, in partnership with the North American Neuroendocrine Tumor Society (NANETS), is pleased to announce that Iacovos Michael, PhD, Scientist at Sunnybrook Research Institute and